Polyubiquitinylation profile in down syndrome brain before and after the development of Alzheimer neuropathology

Antioxidants and Redox Signaling

Volumn 26, Issue 7, 2017, Pages 280-298

  Tramutola, Antonella ^a   Di Domenico, Fabio ^a   Barone, Eugenio ^a   Arena, Andrea ^a   Giorgi, Alessandra ^a   Di Francesco, Laura ^a   Schininà, Maria Eugenia ^a   Coccia, Raffaella ^a   Head, Elizabeth ^b   Butterfield, D Allan ^b,c   Perluigi, Marzia ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF KENTUCKY   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Alzheimer disease; Down syndrome; Proteasome; Proteomics; Trisomy21; Ubiquitin

Indexed keywords

ADENOSINE TRIPHOSPHATE; CHYMOTRYPSIN; PROTEASOME; UBIQUITIN THIOLESTERASE; POLYUBIQUITIN; PROTEIN BINDING;

ADULT; AGED; AGING; ALZHEIMER DISEASE; ARTICLE; BRAIN FUNCTION; BRAIN HOMOGENATE; CONTROLLED STUDY; DOWN SYNDROME; ENERGY METABOLISM; FEMALE; HUMAN; IMMUNOPRECIPITATION; MALE; MIDDLE AGED; NEUROPATHOLOGY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN PROCESSING; PROTEOMICS; TWO DIMENSIONAL ELECTROPHORESIS; WESTERN BLOTTING; ANIMAL; BRAIN; COMPLICATION; GENETICS; METABOLISM; PROCEDURES; REPRODUCIBILITY; UBIQUITINATION;

ALZHEIMER DISEASE; ANIMALS; BRAIN; DOWN SYNDROME; HUMANS; POLYUBIQUITIN; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN BINDING; PROTEOMICS; REPRODUCIBILITY OF RESULTS; UBIQUITIN THIOLESTERASE; UBIQUITINATION;

EID: 85013434336     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2016.6686     Document Type: Article

References (75)

1. Alfano C, Faggiano S, and Pastore A. The ball and chain of poly-ubiquitin structures. Trends Biochem Sci 41: 371-385, 2016.
2. Becker L, Mito T, Takashima S, and Onodera K. Growth and development of the brain in Down syndrome. Prog Clin Biol Res 373: 133-152, 1991.
3. Ben-Zvi A, Miller EA, and Morimoto RI. Collapse of proteostasis represents an early molecular event in Cae-norhabditis elegans aging. Proc Natl Acad Sci U S A 106: 14914-14919, 2009.
4. Butterfield DA, Di Domenico F, Swomley AM, Head E, and Perluigi M. Redox proteomics analysis to decipher the neurobiology of Alzheimer-like neurodegeneration: Overlaps in Down's syndrome and Alzheimer's disease brain. Biochem J 463: 177-189, 2014.
5. Butterfield DA, Perluigi M, Reed T, Muharib T, Hughes CP, Robinson RA, and Sultana R. Redox proteomics in selected neurodegenerative disorders: From its infancy to future applications. Antioxid Redox Signal 17: 1610-1655, 2012.
6. Calabrese V, Sultana R, Scapagnini G, Guagliano E, Sapienza M, Bella R, Kanski J, Pennisi G, Mancuso C, Stella AM, and Butterfield DA. Nitrosative stress, cellular stress response, and thiol homeostasis in patients with Alzheimer's disease. Antioxid Redox Signal 8: 1975-1986, 2006.
7. Castegna A, Aksenov M, Aksenova M, Thongboonkerd V, Klein JB, Pierce WM, Booze R, Markesbery WR, and Butterfield DA. Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part I: Creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. Free Radic Biol Med 33: 562-571, 2002.
8. Cecarini V, Ding Q, and Keller JN. Oxidative inactivation of the proteasome in Alzheimer's disease. Free Radic Res 41: 673-680, 2007.
9. Cenini G, Dowling AL, Beckett TL, Barone E, Mancuso C, Murphy MP, Levine H, 3rd, Lott IT, Schmitt FA, Butterfield DA, and Head E. Association between frontal cortex oxida-tive damage and beta-amyloid as a function of age in Down syndrome. Biochim Biophys Acta 1822: 130-138, 2012.
10. Chauhan V, Ji L, and Chauhan A. Anti-amyloidogenic, anti-oxidant and anti-apoptotic role of gelsolin in Alzheimer's disease. Biogerontology 9: 381-389, 2008.
11. Chen T, Zhou T, He B, Yu H, Guo X, Song X, and Sha J. mUbiSiDa: A comprehensive database for protein ubiqui-tination sites in mammals. PLoS One 9: e85744, 2014.
12. Cisse S, Perry G, Lacoste-Royal G, Cabana T, and Gauvreau D. Immunochemical identification of ubiquitin and heat-shock proteins in corpora amylacea from normal aged and Alzheimer's disease brains. Acta Neuropathol 85: 233-240, 1993.
13. Coskun PE, Wyrembak J, Derbereva O, Melkonian G, Doran E, Lott IT, Head E, Cotman CW, and Wallace DC. Systemic mitochondrial dysfunction and the etiology of Alzheimer's disease and Down syndrome dementia. J Alzheimers Dis 20 Suppl 2: S293-S310, 2010.
14. Cox J, Matic I, Hilger M, Nagaraj N, Selbach M, Olsen JV, and Mann M. A practical guide to the MaxQuant computational platform for SILAC-based quantitative proteomics. Nat Protoc 4: 698-705, 2009.
15. Dantuma NP and Bott LC. The ubiquitin-proteasome system in neurodegenerative diseases: Precipitating factor, yet part of the solution. Front Mol Neurosci 7: 70, 2014.
16. de Haan JB, Cristiano F, Iannello RC, and Kola I. Cu/Zn-superoxide dismutase and glutathione peroxidase during aging. Biochem Mol Biol Int 35: 1281-1297, 1995.
17. Di Domenico F, Coccia R, Cocciolo A, Murphy MP, Cenini G, Head E, Butterfield DA, Giorgi A, Schinina ME, Man-cuso C, Cini C, and Perluigi M. Impairment of proteostasis network in Down syndrome prior to the development of Alzheimer's disease neuropathology: redox proteomics analysis of human brain. Biochim Biophys Acta 1832: 1249-1259, 2013.
18. Di Domenico F, Pupo G, Giraldo E, Badia MC, Monllor P, Lloret A, Eugenia Schinina M, Giorgi A, Cini C, Tramutola A, Butterfield DA, Vina J, and Perluigi M. Oxidative signature of cerebrospinal fluid from mild cognitive impairment and Alzheimer disease patients. Free Radic Biol Med 91: 1-9, 2015.
19. Di Domenico F, Pupo G, Tramutola A, Giorgi A, Schinina ME, Coccia R, Head E, Butterfield DA, and Perluigi M. Redox proteomics analysis of HNE-modified proteins in Down syndrome brain: Clues for understanding the development of Alzheimer disease. Free Radic Biol Med 71: 270-280, 2014.
20. El Ayadi A, Stieren ES, Barral JM, and Boehning D. Ubiquilin-1 and protein quality control in Alzheimer disease. Prion 7: 164-169, 2013.
21. Esser C, Alberti S, and Hohfeld J. Cooperation of molecular chaperones with the ubiquitin/proteasome system. Biochim Biophys Acta 1695: 171-188, 2004.
22. Fergusson J, Landon M, Lowe J, Dawson SP, Layfield R, Hanger DP, and Mayer RJ. Pathological lesions of Alzheimer's disease and dementia with Lewy bodies brains exhibit immunoreactivity to an ATPase that is a regulatory subunit of the 26S proteasome. Neurosci Lett 219: 167-170, 1996.
23. Gimeno A, Garcia-Gimenez JL, Audi L, Toran N, Andaluz P, Dasi F, Vina J, and Pallardo FV. Decreased cell proliferation and higher oxidative stress in fibroblasts from Down syndrome fetuses. Preliminary study. Biochim Biophys Acta 1842: 116-125, 2014.
24. Goldberg AL. Protein degradation and protection against misfolded or damaged proteins. Nature 426: 895-899, 2003.
25. Gulesserian T, Engidawork E, Fountoulakis M, and Lubec G. Antioxidant proteins in fetal brain: Superoxide dismutase-1 (SOD-1) protein is not overexpressed in fetal Down syndrome. J Neural Transm Suppl 71-84, 2001.
26. Hamos JE, Oblas B, Pulaski-Salo D, Welch WJ, Bole DG, and Drachman DA. Expression of heat shock proteins in Alzheimer's disease. Neurology 41: 345-350, 1991.
27. Head E, Lott IT, Wilcock DM, and Lemere CA. Aging in Down syndrome and the development of Alzheimer's disease neuropathology. Curr Alzheimer Res 13: 18-29, 2016.
28. Head E, Silverman W, Patterson D, and Lott IT. Aging and Down syndrome. Curr Gerontol Geriatr Res 2012: 412536, 2012.
29. Helguera P, Pelsman A, Pigino G, Wolvetang E, Head E, and Busciglio J. ets-2 Promotes the activation of a mito-chondrial death pathway in Down's syndrome neurons. J Neurosci 25: 2295-2303, 2005.
30. Hershko A, Ciechanover A, Heller H, Haas AL, and Rose IA. Proposed role of ATP in protein breakdown: conjugation of protein with multiple chains of the polypeptide of ATP-dependent proteolysis. Proc Natl Acad Sci U S A 77: 1783-1786, 1980.
31. Horvath S, Garagnani P, Bacalini MG, Pirazzini C, Salvioli S, Gentilini D, Di Blasio AM, Giuliani C, Tung S, Vinters HV, and Franceschi C. Accelerated epigenetic aging in Down syndrome. Aging Cell 14: 491-495, 2015.
32. Ihara Y, Morishima-Kawashima M, and Nixon R. The ubiquitin-proteasome system and the autophagic-lysosomal system in Alzheimer disease. Cold Spring Harb Perspect Med 2: 1-27, 2012.
33. Ikeda F and Dikic I. Atypical ubiquitin chains: New molecular signals. Protein modifications: Beyond the usual suspects' review series. EMBO Rep 9: 536-542, 2008.
34. Iwai K, Fujita H, and Sasaki Y. Linear ubiquitin chains: NF-kappaB signalling, cell death and beyond. Nat Rev Mol Cell Biol 15: 503-508, 2014.
35. Ji L, Chauhan V, Mehta P, Wegiel J, Mehta S, and Chauhan A. Relationship between proteolytically cleaved gelsolin and levels of amyloid-beta protein in the brains of Down syndrome subjects. J Alzheimers Dis 22: 609-617, 2010.
36. Ji L, Zhao X, and Hua Z. Potential therapeutic implications of gelsolin in Alzheimer's disease. J Alzheimers Dis 44: 13-25, 2015.
37. Jiang Y, Mullaney KA, Peterhoff CM, Che S, Schmidt SD, Boyer-Boiteau A, Ginsberg SD, Cataldo AM, Mathews PM, and Nixon RA. Alzheimer's-related endosome dysfunction in Down syndrome is Abeta-independent but requires APP and is reversed by BACE-1 inhibition. Proc Natl Acad Sci U S A 107: 1630-1635, 2010.
38. Keller JN, Hanni KB, and Markesbery WR. Impaired proteasome function in Alzheimer's disease. J Neurochem 75: 436-439, 2000.
39. Kevei E and Hoppe T. Ubiquitin sets the timer: Impacts on aging and longevity. Nat Struct Mol Biol 21: 290-292, 2014.
40. Kim W, Bennett EJ, Huttlin EL, Guo A, Li J, Possemato A, Sowa ME, Rad R, Rush J, Comb MJ, Harper JW, and Gygi SP. Systematic and quantitative assessment of the ubiquitin-modified proteome. Mol Cell 44: 325-340, 2011.
41. Komander D and Rape M. The ubiquitin code. Annu Rev Biochem 81: 203-229, 2012.
42. Korolchuk VI, Menzies FM, and Rubinsztein DC. Mechanisms of cross-talk between the ubiquitin-proteasome and autophagy-lysosome systems. FEBS Lett 584: 1393-1398, 2010.
43. Kudo T, Iqbal K, Ravid R, Swaab DF, and Grundke-Iqbal I. Alzheimer disease: Correlation of cerebro-spinal fluid and brain ubiquitin levels. Brain Res 639: 1-7, 1994.
44. Kulathu Y and Komander D. Atypical ubiquitylation - The unexplored world of poly-ubiquitin beyond Lys48 and Lys63 linkages. Nat Rev Mol Cell Biol 13: 508-523, 2012.
45. Labudova O, Cairns N, Kitzmuller E, and Lubec G. Impaired brain glucose metabolism in patients with Down syndrome. J Neural Transm Suppl 57: 247-256, 1999.
46. Larsen CN, Krantz BA, and Wilkinson KD. Substrate specificity of deubiquitinating enzymes: Ubiquitin C-terminal hydrolases. Biochemistry 37: 3358-3368, 1998.
47. Lecker SH, Goldberg AL, and Mitch WE. Protein degradation by the ubiquitin-proteasome pathway in normal and disease states. J Am Soc Nephrol 17: 1807-1819, 2006.
48. Li W and Ye Y. Poly-ubiquitin chains: functions, structures, and mechanisms. Cell Mol Life Sci 65: 2397-2406, 2008.
49. Lilienbaum A. Relationship between the proteasomal system and autophagy. Int J Biochem Mol Biol 4: 1-26, 2013.
50. Lopez Salon M, Morelli L, Castano EM, Soto EF, and Pasquini JM. Defective ubiquitination of cerebral proteins in Alzheimer's disease. J Neurosci Res 62: 302-310, 2000.
51. Lott IT, Head E, Doran E, and Busciglio J. Beta-amyloid, oxidative stress and Down syndrome. Curr Alzheimer Res 3: 521-528, 2006.
52. Menzies FM, Fleming A, and Rubinsztein DC. Compromised autophagy and neurodegenerative diseases. Nat Rev Neurosci 16: 345-357, 2015.
53. Nixon RA and Yang DS. Autophagy failure in Alzheimer's disease-Locating the primary defect. Neurobiol Dis 43: 38-45, 2011.
54. Nunomura A, Perry G, Pappolla MA, Friedland RP, Hirai K, Chiba S, and Smith MA. Neuronal oxidative stress precedes amyloid-beta deposition in Down syndrome. J Neuropathol Exp Neurol 59: 1011-1017, 2000.
55. Osaka H, Wang YL, Takada K, Takizawa S, Setsuie R, Li H, Sato Y, Nishikawa K, Sun YJ, Sakurai M, Harada T, Hara Y, Kimura I, Chiba S, Namikawa K, Kiyama H, Noda M, Aoki S, and Wada K. Ubiquitin carboxy-terminal hy-drolase L1 binds to and stabilizes monoubiquitin in neuron. Hum Mol Genet 12: 1945-1958, 2003.
56. Pagano G and Castello G. Oxidative stress and mitochon-drial dysfunction in Down syndrome. Adv Exp Med Biol 724: 291-299, 2012.
57. Perluigi M, Di Domenico F, and Butterfield DA. mTOR signaling in aging and neurodegeneration: At the crossroad between metabolism dysfunction and impairment of au-tophagy. Neurobiol Dis 84: 39-49, 2015.
58. Perluigi M, di Domenico F, Fiorini A, Cocciolo A, Giorgi A, Foppoli C, Butterfield DA, Giorlandino M, Giorlandino C, Schinina ME, and Coccia R. Oxidative stress occurs early in Down syndrome pregnancy: A redox proteomics analysis of amniotic fluid. Proteomics Clin Appl 5: 167-178, 2011.
59. Perluigi M, Pupo G, Tramutola A, Cini C, Coccia R, Barone E, Head E, Butterfield DA, and Di Domenico F. Neuro-pathological role of PI3K/Akt/mTOR axis in Down syndrome brain. Biochim Biophys Acta 1842: 1144-1153, 2014.
60. Radivojac P, Vacic V, Haynes C, Cocklin RR, Mohan A, Heyen JW, Goebl MG, and Iakoucheva LM. Identification, analysis, and prediction of protein ubiquitination sites. Proteins 78: 365-380, 2010.
61. Rappsilber J, Mann M, and Ishihama Y. Protocol for micropurification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips. Nat Protoc 2: 1896-1906, 2007.
62. Roper RJ and Reeves RH. Understanding the basis for Down syndrome phenotypes. PLoS Genet 2: e50, 2006.
63. Rothenberg C and Monteiro MJ. Ubiquilin at a crossroads in protein degradation pathways. Autophagy 6: 979-980, 2010.
64. Sawa A. Neuronal cell death in Down's syndrome. J Neural Transm Suppl 57: 87-97, 1999.
65. Setsuie R and Wada K. The functions of UCH-L1 and its relation to neurodegenerative diseases. Neurochem Int 51: 105-111, 2007.
66. Silva GM, Finley D, and Vogel C. K63 poly-ubiquitination is a new modulator of the oxidative stress response. Nat Struct Mol Biol 22: 116-123, 2015.
67. Stieren ES, El Ayadi A, Xiao Y, Siller E, Landsverk ML, Oberhauser AF, Barral JM, and Boehning D. Ubiquilin-1 is a molecular chaperone for the amyloid precursor protein. J Biol Chem 286: 35689-35698, 2011.
68. Tanaka K and Matsuda N. Proteostasis and neurodegen-eration: The roles of proteasomal degradation and autop-hagy. Biochim Biophys Acta 1843: 197-204, 2014.
69. Tramutola A, Pupo G, Di Domenico F, Barone E, Arena A, Lanzillotta C, Broekaart D, Blarzino C, Head E, Butterfield D, and Perluigi M. Activation of p53 in Down syndrome and in the Ts65Dn mouse brain is associated with a pro-apoptotic phenotype. J Alzheimers Dis 52: 359-371, 2016.
70. Triplett JC, Swomley AM, Cai J, Klein JB, and Butterfield DA. Quantitative phosphoproteomic analyses of the inferior parietal lobule from three different pathological stages of Alzheimer's disease. J Alzheimers Dis 49: 45-62, 2015.
71. Wickliffe KE, Williamson A, Meyer HJ, Kelly A, and Rape M. K11-linked ubiquitin chains as novel regulators of cell division. Trends Cell Biol 21: 656-663, 2011.
72. Wiseman FK, Al-Janabi T, Hardy J, Karmiloff-Smith A, Nizetic D, Tybulewicz VL, Fisher EM, and Strydom A. A genetic cause of Alzheimer disease: Mechanistic insights from Down syndrome. Nat Rev Neurosci 16: 564-574, 2015.
73. Wolfe DM, Lee JH, Kumar A, Lee S, Orenstein SJ, and Nixon RA. Autophagy failure in Alzheimer's disease and the role of defective lysosomal acidification. Eur J Neu-rosci 37: 1949-1961, 2013.
74. Xu P, Duong DM, Seyfried NT, Cheng D, Xie Y, Robert J, Rush J, Hochstrasser M, Finley D, and Peng J. Quantitative proteomics reveals the function of unconventional ubiquitin chains in proteasomal degradation. Cell 137: 133-145, 2009.
75. Zana M, Janka Z, and Kalman J. Oxidative stress: A bridge between Down's syndrome and Alzheimer's disease. Neu-robiol Aging 28: 648-676, 2007.